{"transactions":[{"id":770191,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Dev. Off"}}],"security":"Common Stock","published_at":"2026-05-20T20:31:20.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":45887,"price":0.8967,"value":41146.8729,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person.  This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person."}],"balance_after":267213,"source":{"system":"sec-edgar","filing":"0001878193-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000187819326000002/ownership.xml","form_type":"4"}},{"id":997951,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2025-11-17T22:52:29.000Z","date":"2025-11-16","kind":"grant","planned":false,"acquired":true,"shares":311100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027."}],"balance_after":313100,"source":{"system":"sec-edgar","filing":"0001628280-25-052723","document":"wk-form4_1763419946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000162828025052723/wk-form4_1763419946.xml","form_type":"4"}},{"id":1172680,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2025-04-14T13:00:23.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.53,"value":30600.0,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":40600,"source":{"system":"sec-edgar","filing":"0001818382-25-000050","document":"wk-form4_1744635615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838225000050/wk-form4_1744635615.xml","form_type":"4"}},{"id":1296531,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T21:34:14.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":283101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":283101,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":283101},"source":{"system":"sec-edgar","filing":"0001818382-25-000016","document":"wk-form4_1737668047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838225000016/wk-form4_1737668047.xml","form_type":"4"}},{"id":1324316,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2024-12-20T22:09:32.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant."}],"balance_after":2625,"derivative":{"exercise_price":10.28,"exercise_date":"2024-12-19","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-24-000230","document":"wk-form4_1734732566.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000230/wk-form4_1734732566.xml","form_type":"4"}},{"id":1420037,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2024-08-29T22:45:12.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":39389,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.56,"exercise_date":"2018-09-01","expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":39389},"source":{"system":"sec-edgar","filing":"0001818382-24-000165","document":"wk-form4_1724971323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000165/wk-form4_1724971323.xml","form_type":"4"}},{"id":1420036,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2024-08-29T22:45:12.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":39389,"price":6.68,"value":263118.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001818382-24-000165","document":"wk-form4_1724971323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000165/wk-form4_1724971323.xml","form_type":"4"}},{"id":1420035,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2024-08-29T22:45:12.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":39389,"price":2.56,"value":100835.84,"ownership":{"direct":true},"balance_after":41389,"source":{"system":"sec-edgar","filing":"0001818382-24-000165","document":"wk-form4_1724971323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000165/wk-form4_1724971323.xml","form_type":"4"}},{"id":1714565,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2023-12-12T21:09:45.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant."}],"balance_after":2100,"derivative":{"exercise_price":10.28,"exercise_date":"2023-12-11","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-23-000193","document":"wk-form4_1702415371.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838223000193/wk-form4_1702415371.xml","form_type":"4"}},{"id":1714564,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2023-12-12T21:09:45.000Z","date":"2023-12-08","kind":"grant","planned":false,"acquired":true,"shares":301000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027."}],"balance_after":301000,"derivative":{"exercise_price":2.8,"expiration_date":"2033-12-08","underlying":"Common Stock","underlying_shares":301000},"source":{"system":"sec-edgar","filing":"0001818382-23-000193","document":"wk-form4_1702415371.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838223000193/wk-form4_1702415371.xml","form_type":"4"}},{"id":2082035,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2022-12-20T01:29:24.000Z","date":"2022-12-16","kind":"purchase","acquired":true,"shares":20000,"price":2.6,"value":52000.0,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":20600,"source":{"system":"sec-edgar","filing":"0001818382-22-000224","document":"wf-form4_167149975005868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838222000224/wf-form4_167149975005868.xml","form_type":"4"}},{"id":2082034,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2022-12-20T01:29:24.000Z","date":"2022-12-13","kind":"other","acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":600,"source":{"system":"sec-edgar","filing":"0001818382-22-000224","document":"wf-form4_167149975005868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838222000224/wf-form4_167149975005868.xml","form_type":"4"}},{"id":2089940,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2022-12-12T21:14:57.000Z","date":"2022-12-08","kind":"grant","acquired":true,"shares":136000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026."}],"balance_after":136000,"derivative":{"exercise_price":3.07,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":136000},"source":{"system":"sec-edgar","filing":"0001818382-22-000200","document":"wf-form4_167087967122662.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838222000200/wf-form4_167087967122662.xml","form_type":"4"}},{"id":2266018,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2022-05-18T22:16:49.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":2000,"price":4.53,"value":9060.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001104659-22-062583","document":"tm2216009-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000110465922062583/tm2216009-1_4seq1.xml","form_type":"4"}},{"id":2588574,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:09:22.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":210077,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options vest annually in three equal installments on 05/14/2022, 05/14/2023, and 05/14/2024."}],"balance_after":210077,"derivative":{"exercise_price":10.28,"exercise_date":"2022-05-14","expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":210077},"source":{"system":"sec-edgar","filing":"0001104659-21-110523","document":"tm2125954-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000110465921110523/tm2125954-15_4seq1.xml","form_type":"4"}},{"id":2588573,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:09:22.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":183817,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vest annually in three equal installments on 11/09/2021, 11/09/2022, and 11/09/2023."}],"balance_after":183817,"derivative":{"exercise_price":10.28,"exercise_date":"2021-11-09","expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":183817},"source":{"system":"sec-edgar","filing":"0001104659-21-110523","document":"tm2125954-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000110465921110523/tm2125954-15_4seq1.xml","form_type":"4"}},{"id":2588572,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:09:22.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":1575,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant."}],"balance_after":1575,"derivative":{"exercise_price":10.28,"exercise_date":"2021-12-14","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":1575},"source":{"system":"sec-edgar","filing":"0001104659-21-110523","document":"tm2125954-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000110465921110523/tm2125954-15_4seq1.xml","form_type":"4"}},{"id":2588571,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:09:22.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":17068,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are fully vested and exercisable."}],"balance_after":17068,"derivative":{"exercise_price":6.54,"expiration_date":"2028-04-12","underlying":"Common Stock","underlying_shares":17068},"source":{"system":"sec-edgar","filing":"0001104659-21-110523","document":"tm2125954-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000110465921110523/tm2125954-15_4seq1.xml","form_type":"4"}},{"id":2588570,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2021-08-27T20:09:22.000Z","date":"2021-08-26","kind":"grant","acquired":true,"shares":39389,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 26, 2021, Alpha Healthcare Acquisition Corp. (\"AHAC\") consummated a business combination (the \"Business Combination\") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (\"Hunter Merger Sub\") and Humacyte, Inc., a Delaware corporation (\"Legacy Humacyte\"), AHAC changed its name to \"Humacyte, Inc.\" and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are fully vested and exercisable."}],"balance_after":39389,"derivative":{"exercise_price":2.56,"expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":39389},"source":{"system":"sec-edgar","filing":"0001104659-21-110523","document":"tm2125954-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000110465921110523/tm2125954-15_4seq1.xml","form_type":"4"}}]}